389 |
Better Diabetic Performance in TAXUS |
Antonio Colombo |
Oct. 05. 07 |
388 |
The Science Behind Xience V |
Jacques J. Koolen |
Sep. 28. 07 |
387 |
SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent) |
Gregg W. Stone |
Sep. 28. 07 |
386 |
DES Safety Concerns: Impact on Clinical Practice |
Martin Bert Leon |
Sep. 28. 07 |
385 |
What Makes Endeavor Different |
Alan C. Yeung |
Sep. 28. 07 |
384 |
Endeavor - Combining Safety with Efficacy |
Eulogio Garcia |
Sep. 28. 07 |
383 |
Endeavor Clinical Program Overview |
Marco A. Costa |
Sep. 28. 07 |
382 |
Visionable Performance of Next Generation of DES |
Duncan Hung Kwong Ho |
Sep. 20. 07 |
381 |
The J-Cypher Registry Update |
Takeshi Kimura |
Sep. 20. 07 |
380 |
Is DES Deployment Technique Associated with Late Stent Thrombosis?; New Insights from the STLLR Trial |
Marco A. Costa |
Sep. 20. 07 |